Archives
- 2026-06
- 2026-05
- 2026-04
- 2026-03
- 2026-02
- 2026-01
- 2025-12
- 2025-11
- 2025-10
- 2025-09
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-07
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
- 2021-12
- 2021-11
- 2021-10
- 2021-09
- 2021-08
- 2021-07
- 2021-06
- 2021-05
- 2021-04
- 2021-03
- 2021-02
- 2021-01
- 2020-12
- 2020-11
- 2020-10
- 2020-09
- 2020-08
- 2020-07
- 2020-06
- 2020-05
- 2020-04
- 2020-03
- 2020-02
- 2020-01
- 2019-12
- 2019-11
- 2019-10
- 2019-09
- 2019-08
- 2019-07
- 2018-07
-
Aspartame l aspartyl l phenylalanine methylester
2022-05-27

Aspartame (l-aspartyl l-phenylalanine methylester) is a dipeptide artificial sweetener that is widely used as a non-nutritive sweetener in various food products [1]. The increased market of dietary products and the development of new synthetic sweetening compounds have not been sufficiently explored
-
The inhibition of NSAIDs towards GLOI provides a direction
2022-05-26

The inhibition of NSAIDs towards GLOI provides a direction for the development of novel effective GLOI inhibitors. Although the inhibitory activity of indomethacin was determined and the interactions between it Artemisinine and GLOI were probed by NMR titration experiments, no detailed inhibitory m
-
br Results br Discussion br Materials
2022-05-26

Results Discussion Materials and Methods Introduction Deoxyribonucleic BAY 41-8543 (DNA) is among the most important biopolymers in living organisms alongside carbohydrates and proteins. DNA is a linear polymer consisting of four types of nucleobases, deoxyribose, and phosphate. The bac
-
A number of GCK activators for treating
2022-05-26

A number of GCK activators for treating T2D have been developed and tested but not progressed successfully from clinical trials into therapy [45]. Our observations suggest that increased risk of hypoglycemia might be possible, particularly if drugs penetrate into brain. A further possibility is that
-
Analogous to all GPCRs the GLP R transduces signals from
2022-05-26

Analogous to all GPCRs, the GLP-1R transduces signals from the outside of the cell to the inside by allosterically converting a ligand-binding event to activation of intracellular effectors. The GLP-1R couples to several intracellular effectors and this pleiotropic coupling is physiologically releva
-
When PKC was applied alone it
2022-05-26

When PKC19–31 was applied alone, it attenuated the activity run-down following excision. Furthermore, the activity induced by addition of PKC19–31 during PMA treatment in many cases was higher than in controls. Accordingly, in our experimental conditions, the mechanism which underlays channel inhibi
-
Herein we describe the development of second
2022-05-26

Herein, we describe the development of second generation GSM compounds aimed at improving critical physicochemical properties while maintaining the potent activity of the parent AGSM. Ligand design focused on identifying heterocyclic replacements for the hydrophobic D-ring as a means to improve ADME
-
Based upon the present findings it is tempting to
2022-05-26

Based upon the present findings, it is tempting to imagine that selective, and especially stable blood–brain barrier (BBB) penetrating GalR1 antagonists might be useful as drugs for acute suppression of appetite. While this may be possible, previous studies using nonspecific galanin antagonists yiel
-
Gal is a amino acid residue peptide comprising amino
2022-05-26

Gal is a 29-amino Immunology Compound Library receptor residue peptide, comprising 30 amino acids in humans, isolated from the porcine intestine 30 years ago (Tatemoto et al., 1983). It has been shown to be involved in the regulation of numerous processes, including neuroendocrine control of system
-
br Materials and methods br Results br Discussion Although h
2022-05-26

Materials and methods Results Discussion Although homologues of the β-galactosidase gene were known to exist in the Xenopus genome, and SA-β-gal activity has been detected in whole-mount Xenopus embryos by histochemical staining (Davaapil et al., 2017), no reports have been presented so far
-
Metabolic adaptation is an important survival strategy for c
2022-05-25

Metabolic adaptation is an important survival strategy for cancer cells within the hypoxic tumor environment. Under the condition of O2 limitation, metabolic pathways shift from energy-efficient oxidative phosphorylation to the anaerobic glycolysis pathway for the purpose of ATP generation [13,43].
-
The lactic acid receptor HCA is primarily
2022-05-25

The lactic Phosphatase Inhibitor Cocktail 2 (100X in ddH2O) receptor HCA1 is primarily expressed in white and brown adipocytes 11, 12, 17, 18 (Table 1). Only relatively low expression levels of HCA1 have been described in several other tissues 16, 19, and it is not clear whether this is due to the
-
Fluorescein TSA Fluorescence System Kit br Concluding remark
2022-05-25

Concluding remarks Several orphan GPCRs have expression profiles that indicate they are worthy of consideration as therapeutic targets. This view can be supported via various transgenic techniques, and it would be interesting to have wide-ranging phenotypic information on GPR35 knockout mice. Bas
-
pdgfr inhibitor The first described synthetic FFA active ago
2022-05-25

The first described synthetic FFA1 active agonist, GW9508 (4- [(3-phenoxyphenyl)methyl]amino benzenepropanoic acid), was immediately shown to also activate FFA4, although with some 100-fold lower potency [38]. Therefore, in the initial absence of FFA4-selective synthetic agonist ligands, GW9508 was
-
e 64 synthesis br Acknowledgements We thank the support of t
2022-05-25

Acknowledgements We thank the support of the National Natural Science Foundation of China (NSFC) project 81501342 and support from the Disciplinary Group of Oncology and Immunology program of Xinxiang Medical University. Introduction First described as a new clinical entity in 1981, the Acqui
15593 records 471/1040 page Previous Next First page 上5页 471472473474475 下5页 Last page